Oxazepam

Most commercial benzodiazepine immunoassay screening panels target oxazepam as the primary analyte because it is a common terminal metabolite of diazepam, nordiazepam, temazepam, chlordiazepoxide, and clorazepate. Laboratory testing applications include drugs of abuse screening, pain management compliance monitoring, forensic toxicology investigations, postmortem toxicology, driving under the influence of drugs (DUID) cases, and clinical toxicology assessments, where oxazepam detection may indicate use of the parent drug or metabolism from other benzodiazepines. UTAK’s Benzodiazepines Plus panels contain oxazepam in lyophilized urine and whole blood matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods. Stock and custom QC solutions can incorporate related benzodiazepines such as diazepam, nordiazepam, temazepam, alprazolam, clonazepam, lorazepam, and other commonly monitored sedative-hypnotics to address your laboratory’s comprehensive benzodiazepine testing requirements.